Clinical Trial Update: Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pembrolizumab in combination with lenvatinib for ovarian clear cell carcinoma; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gynecologic Cancer
• Ovarian Clear Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Elizabeth K. Lee MD | Conditions: Ovarian Clear Cell Carcinoma, Gynecologic Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING